Skip to main content
    E

    Eli Lilly and Company (LLY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $1252.24
    +43.50 (+3.60%)

    Market Cap: $1.08T

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    74%(29/39)
    Avg Surprise
    +10.81%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$8.09
    Range$4.65 - $11.30
    17 analysts
    EPS Revisions
    2
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$9.43-14.1%
    60d ago$9.78-17.2%
    30d ago$9.87-18.0%
    7d ago$9.96-18.7%
    Current$8.09
    Revenue Consensus
    $22.4B
    Range$21.4B - $24.0B
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$14.30
    Range$9.86 - $19.30
    27 analysts
    Revenue Consensus
    $27.6B
    Range$22.6B - $31.6B
    28 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$14.30---
    Sep 26EST
    		-$8.09---
    Jun 26
    Reported Aug 5
    		$8.38$6.01+39.43%Beat+32.8%
    Mar 26
    Reported Apr 30
    		$8.55$6.79+25.92%Beat+156.0%
    Dec 25
    Reported Feb 4
    		$7.54$7.17+5.16%Beat+41.7%
    Sep 25
    Reported Oct 30
    		$7.02$5.89+19.19%Beat+494.9%
    Jun 25
    Reported Aug 7
    		$6.31$5.61+12.48%Beat+61.0%
    Mar 25
    Reported May 1
    		$3.34$3.46-3.47%Miss+29.5%
    Dec 24
    Reported Feb 6
    		$5.32$5.07+5.00%Beat+113.7%
    Sep 24
    Reported Oct 30
    		$1.18$1.47-19.73%Miss+1080.0%
    Jun 24
    Reported Aug 8
    		$3.92$2.77+41.52%Beat+85.8%
    Mar 24
    Reported Apr 30
    		$2.58$2.49+3.61%Beat+59.3%
    Dec 23
    Reported Feb 6
    		$2.49$2.37+5.06%Beat+19.1%
    Sep 23
    Reported Nov 2
    		$0.10$-0.12+183.33%Beat-94.9%
    Jun 23
    Reported Aug 8
    		$2.11$1.99+6.03%Beat+68.8%
    Mar 23
    Reported Apr 27
    		$1.62$1.73-6.36%Miss-38.2%
    Dec 22
    Reported Feb 2
    		$2.09$1.83+14.21%Beat-16.1%
    Sep 22
    Reported Nov 1
    		$1.98$1.94+2.06%Beat+2.1%
    Jun 22
    Reported Aug 4
    		$1.25$1.70-26.47%Miss-33.2%
    Mar 22
    Reported Apr 28
    		$2.62$2.29+14.41%Beat+40.1%
    Dec 21
    Reported Feb 3
    		$2.49$2.51-0.80%Miss-9.5%
    Sep 21
    Reported Oct 26
    		$1.94$1.96-1.02%Miss+26.0%
    Jun 21
    Reported Aug 3
    		$1.87$1.89-1.06%Miss-1.1%
    Mar 21
    Reported Apr 27
    		$1.87$2.10-10.95%Miss+6.9%
    Dec 20
    Reported Jan 29
    		$2.75$2.39+15.06%Beat+59.0%
    Sep 20
    Reported Oct 27
    		$1.54$1.71-9.94%Miss+4.1%
    Jun 20
    Reported Jul 30
    		$1.89$1.60+18.13%Beat+26.0%
    Mar 20
    Reported Apr 23
    		$1.75$1.48+18.24%Beat+31.6%
    Dec 19
    Reported Jan 30
    		$1.73$1.52+13.82%Beat+30.1%
    Sep 19
    Reported Oct 23
    		$1.48$1.41+4.96%Beat+6.5%
    Jun 19
    Reported Jul 30
    		$1.50$1.45+3.45%Beat+0.0%
    Mar 19
    Reported Apr 30
    		$1.33$1.33+0.00%Beat-0.7%
    Dec 18
    Reported Feb 6
    		$1.33$1.33+0.00%Beat+16.7%
    Sep 18
    Reported Nov 6
    		$1.39$1.35+2.96%Beat+32.4%
    Jun 18
    Reported Jul 24
    		$1.50$1.30+15.38%Beat+35.1%
    Mar 18
    Reported Apr 24
    		$1.34$1.13+18.58%Beat+36.7%
    Dec 17
    Reported Jan 31
    		$1.14$1.07+6.54%Beat+20.0%
    Sep 17
    Reported Oct 24
    		$1.05$1.03+1.94%Beat-
    Jun 17
    Reported Jul 25
    		$1.11$1.05+5.71%Beat-
    Mar 17
    Reported Apr 25
    		$0.98$0.96+2.08%Beat-
    Dec 16
    Reported Jan 31
    		$0.95$0.98-3.06%Miss-

    Dividends

    Dividend Metrics

    Forward Yield0.55%
    Forward Annual Dividend$6.92
    Payout Ratio21.26%
    FrequencyQuarterly
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+15.24%
    5Y CAGR+15.18%
    LLY dividend history and ex-dividend datesRun LLY in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio39.77EV/EBITDA32.60x
    Price/FCF61.43xFCF Yield1.63%
    Profitability
    Profit Margin33.50%Operating Margin54.20%
    ROE102.30%ROIC30.08%
    Financial Health
    Debt/Equity1.62xInterest CoverageN/A
    Current Ratio1.35xQuick Ratio1.00x
    Trading Statistics
    Beta0.45Avg Volume2.34M
    52-Week High$1292.6552-Week Low$778.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1179.12
    SMA 20$1173.59
    SMA 50$1178.84
    SMA 200$1077.18
    EMA 10$1190.18
    EMA 20$1178.34
    EMA 50$1169.37
    EMA 200$1081.45

    MACD

    Line: 10.71Signal: 2.57Hist: 8.14

    ADX

    ADX: 21.2+DI: 31.4-DI: 12.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down4.0
    PSAR$1132.92

    Bollinger Bands

    Upper Band$1224.35
    Lower Band$1122.83
    %B Position865%(Upper)
    Band Width1.27

    RSI (14-Day)

    Neutral
    67.9

    Momentum Oscillators

    Stoch %K72.2
    Stoch %D63.5
    Williams %R-16.3
    ROC (10d)8.9%
    Momentum102.39
    CCI (20d)331.7
    MFI (14d)56.3

    Volatility Measures

    ATR (14d)$36.76(2.9%)
    StdDev (20d)25.38
    Hist Vol26.7%(Moderate)

    Volume Flow

    VWAP$1252.95
    OBV109.2M
    AD Line-258.2M
    CMF (20d)0.086

    Volume Metrics

    Avg Vol (20d)2.4M
    Vol Ratio1.5x(High)
    VWMA (20d)$1175.13

    Pivot Points

    R3$1268.03
    R2$1242.37
    R1$1225.56
    Pivot Point$1199.90
    S1$1183.08
    S2$1157.42
    S3$1140.61

    Advanced Oscillators

    TSI11.28
    Ultimate Osc59.9
    KST8.65

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$22.97B$19.80B$19.29B$17.60B$15.56B$12.73B$13.53B$11.44B$11.30B$8.77B$9.35B$9.50B
    Cost of Revenue$3.27B$3.58B$3.37B$3.01B$2.45B$2.23B$2.40B$2.17B$2.17B$1.67B$1.79B$1.86B
    Gross Profit$19.71B$16.22B$15.92B$14.59B$13.11B$10.50B$11.13B$9.27B$9.13B$7.09B$7.57B$7.64B
    Operating Expenses$10.73B$7.31B$7.55B$7.23B$6.24B$6.81B$5.98B$7.74B$5.42B$4.59B$5.18B$7.19B
    R&D$6.59B$4.09B$4.33B$4.12B$3.49B$4.31B$3.21B$5.56B$2.87B$2.63B$3.19B$5.38B
    SG&A$3.43B$2.93B$3.13B$2.74B$2.75B$2.47B$2.42B$2.10B$2.12B$1.95B$1.93B$1.80B
    Operating Income$8.98B$8.91B$8.37B$7.37B$6.87B$3.69B$5.15B$1.53B$3.71B$2.51B$2.39B$450.40M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$65.00M$108.30M$133.10M$90.00M$239.00M$110.50M$0$197.60M$0$0$23.20M
    Income Before Tax$9.25B$8.85B$8.27B$7.23B$6.78B$3.46B$5.04B$1.59B$3.52B$2.54B$2.51B$427.20M
    Income Tax Expense$2.15B$1.45B$1.63B$1.65B$1.12B$697.00M$628.50M$618.10M$550.20M$293.20M$318.90M$484.60M
    Net Income$7.09B$7.40B$6.64B$5.58B$5.66B$2.76B$4.41B$970.30M$2.97B$2.24B$2.19B$-57,400,000
    EBITDA$9.78B$9.36B$8.85B$7.70B$7.25B$3.92B$5.52B$2.06B$3.93B$2.94B$2.90B$838.20M
    EBIT$9.25B$8.85B$8.27B$7.23B$6.78B$3.46B$5.04B$1.59B$3.52B$2.54B$2.51B$427.20M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    You Already Own the AI Trade. The Real Question Is What Else You Own.

    Passive S&P ownership is de facto an AI-concentrated active bet - top 10 names ~40% of the S&P, NVDA ~8% and ~USD5T market cap, making the benchmark fragile to a handful of tech outcomes Being right on AI is not the same as proper sizing - I own GOOGL and NVDA...

    Glenn Ford
    •
    6/26/26
    •
    251
    AI Stocks, Barbell Strategy
    Also mentions:
    NVDAVICILLYTSMCAT

    Code or Gold: The Only Barbell That Makes Sense Right Now

    Macro thesis - market structure is bifurcating, forcing capital to choose sides, with the economic middle at risk of structural decline from H2 2026 through 2030 and beyond Alphabet data shows token processing rose from 9.7 trillion to 3.2 quadrillion monthly, a >300x increase...

    Leo Nelissen
    •
    6/11/26
    •
    283
    Macro Strategy
    Also mentions:
    GOOGLMSFTLLYWMBKMI

    The Biggest Healthcare Disconnect In Decades - And The Stocks I’m Watching

    Healthcare has hit a 26-year relative low, but weakness alone does not make the sector a buy. AI-led capital flows, patent cliffs, IRA pricing pressure, and GLP-1 disruption explain much of the selloff. I prefer selective exposure: picks-and-shovels, AI-driven platforms...

    Leo Nelissen
    •
    5/25/26
    •
    459
    Healthcare Stocks, Dividend Investing, value investing
    Also mentions:
    TMOWSTLLYISRGPFE

    Why Eli Lilly is the Market’s Most Misunderstood AI Winner

    Eli Lilly has evolved from legacy pharma into a tech-enabled biology platform, using its proprietary supercomputer and 24/7 robotic wet labs to engineer drugs in silico with NVIDIA AI. The 2026 launch of Foundayo (an oral GLP-1 pill) bypasses complex sterile injector supply bottlenecks...

    Leo Nelissen
    •
    4/9/26
    •
    156

    Incyte’s Earnings: Strong Growth Amid Market Overlook

    INCY generates $1.17B annual FCF with 93% gross margins and zero leverage, yet trades at 15.6x earnings. Reverse-DCF implies ~0% growth priced in. Quality Score 100/100 with ROIC 25.4%, Piotroski 8/9, interest coverage 702x...

    Glenn Ford
    •
    2/11/26
    •
    147
    Biotech, Healthcare Stocks
    Also mentions:
    NVSLLYREGNGILD

    Government Contracts

    Gov Obligations (TTM)
    $281860
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    2
    Avg Remaining Term
    3.5 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25026N0080Department of Veterans AffairsDepartment of Veterans Affairs$229741Oct 6, 2025
    36C26226N0579Department of Veterans AffairsDepartment of Veterans Affairs$52119Jun 1, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Eli Lilly stock: Wells Fargo maintains Buy rating for Eli Lilly stock at USD 1,330.00

    Wells Fargo has maintained its "Buy" rating for Eli Lilly stock with a price target of USD 1,330.00. This target is 5.17% above the current home-market price. Eli Lilly is scheduled to announce its third-quarter 2026...

    ad-hoc-news.de•10/16/26•Bullish

    AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?

    AbbVie (ABBV) has seen its shares rise over 23% year-to-date, outperforming the broader market. Its forward P/E ratio is 16.39x, and the company is successfully transitioning away from Humira dependence...

    Yahoo Finance•10/16/26•Neutral

    Lilly, Pfizer, J&J among winners of EU drug recommendations this month

    An expert panel of the EU drug regulator has recommended six new medicines and five label expansions for approval in October 2026. This marks significant regulatory wins for companies like Eli Lilly, Pfizer...

    Seeking Alpha•10/16/26•Bullish

    Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up

    The weight-loss drug market is projected to reach $100 billion in annual sales within the next decade, leading to intense competition among biotech and pharmaceutical companies. Major players like Novo Nordisk and Eli...

    KSL News•10/16/26•Bullish

    Eli Lilly's weight-loss pill wins EU drug regulator's backing

    The European Medicines Agency's committee has recommended approval for Eli Lilly's weight-loss pill, Foundayo, making it the second oral obesity drug to receive such backing after Novo Nordisk's Wegovy. This...

    Reuters•10/16/26•Bullish

    LLY Valuation and Fair Value

    P/E
    39.8x
    Forward P/E
    24.4x
    EV/EBITDA
    32.6x
    P/FCF
    61.4x
    PEG
    1.1x
    P/B
    33.0x
    See GNG's fair value

    LLY Profitability: Margins, ROIC and FCF

    Gross margin
    83.4%
    Operating margin
    54.2%
    Net margin
    33.5%
    ROIC
    30.1%
    ROE
    102.3%
    FCF margin
    22.8%
    FCF yield
    1.6%

    LLY Competitors

    CompanyTicker
    Johnson & JohnsonJNJ
    AbbVie IncABBV
    Merck & Company IncMRK
    UnitedHealth Group IncorporatedUNH
    Novartis AG ADRNVS
    AstraZeneca PLCAZN
    Thermo Fisher Scientific IncTMO
    Amgen IncAMGN

    Sector: Healthcare

    LLY Analyst Ratings

    Consensus
    Buy
    Analysts
    30
    Strong Buy
    6
    Buy
    19
    Hold
    3
    Sell
    1
    Strong Sell
    1

    LLY Bull Case vs Bear Case

    Bull case

    • LLY earns a 30.1% return on invested capital.
    • LLY converts 22.8% of revenue into free cash flow.
    • LLY has a 33.5% net profit margin.

    LLY Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    10.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $8.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    LLY Dividend

    Forward yield
    0.6%
    Payout ratio
    21.3%
    3Y DPS growth
    15.2%
    5Y DPS growth
    15.2%
    Pay months
    Mar, Jun, Sep, Dec
    LLY dividend history

    Frequently Asked Questions About LLY

    What is LLY's current dividend yield?

    Eli Lilly and Company (LLY) has a forward dividend yield of 0.55%.

    Does LLY pay dividends?

    Yes, Eli Lilly and Company pays dividends with a forward dividend yield of 0.55%.

    What is LLY's P/E ratio?

    Eli Lilly and Company has a price-to-earnings (P/E) ratio of 39.77.

    What is LLY's market cap?

    Eli Lilly and Company (LLY) has a market capitalization of $1.08T with a current stock price of $1252.24.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In